Author: therawinformant

Although some stocks have rebounded from the 2020 market crash, there are still a number of cheap shares available to buy. They may experience short-term uncertainty, but have the potential to produce impressive returns in the long run as the economy recovers.

Warren Buffett has previously purchased cheap stocks to benefit from their capital return potential. Through following his lead, you could improve your chances of making a million in the coming years.

Buying cheap stocks after a market crash

Many investors may naturally be cautious about the prospect of buying cheap stocks after a market crash. After all, the uncertain global economic outlook means there is a very real threat that their prices will move lower in the coming months.

However, undervalued stocks have historically been a sound investment. They enable investors to buy companies at prices that are, in many cases, significantly lower than their intrinsic values. As the economy’s outlook gradually improves, and investor sentiment does likewise, bargain shares are likely to have greater scope to register large capital gains than fairly valued businesses.

Therefore, the market crash has created numerous buying opportunities for investors. Previous bear markets have always been followed by bull markets, which is likely to be the case following the stock market’s recent decline.

Risk management

Of course, not every cheap stock will recover after the market crash. Some industries and businesses may struggle to compete in what could prove to be a very different post-coronavirus economy. For example, retailers that lack an online presence may struggle to compete with e-commerce rivals, while energy companies may need to reinvest more heavily in greener alternatives to fossil fuels.

As such, it could be a shrewd move to build a diverse portfolio of undervalued stocks. Through having exposure to a variety of sectors and geographies, you can reduce your reliance on one particular industry or region. Given the uncertain economic environment facing many companies, this could prove to be a logical step for all investors to take.

Making a million

Even though buying cheap stocks after a market crash could improve your chances of making a million, it is unlikely to be a quick process. Even Warren Buffett took many years to build his wealth through adopting a similar strategy.

However, by giving your holdings the time they require to implement revised strategies and for investor sentiment to improve, it is possible to make a million. For example, the stock market has produced annualised total returns of around 8% over recent decades. By investing $500 per month over a 35-year time period, you could generate a seven-figure portfolio through earning the market return.

By investing in cheap stocks after the market crash, you may be able to obtain an even higher rate of return, thereby making a seven-figure portfolio a more realistic aim over the long run. 

More reading

• Why the Tesla (NASDAQ:TSLA) share price zoomed 12.5% higher
• Why the Clinuvel (ASX:CUV) share price is storming higher today
• Catapult (ASX:CAT) share price charges higher on French Rugby deal
• AstraZeneca resumes UK clinical trials of its coronavirus vaccine after a safety pause
• Pfizer says it could know if its COVID-19 vaccine candidate works in October

Motley Fool contributor Peter Stephens has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post I’d follow Warren Buffett and buy cheap stocks after the market crash to make a million appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3c0zBwH

The CLINUVEL Pharmaceuticals Limited (ASX: CUV) share price is pushing higher on Tuesday following the release of an announcement.

At the time of writing the biopharmaceutical company’s shares are up 3% to $21.96.

What did CLINUVEL announce?

This morning the company provided an update on its plans to expand the use of its SCENESSE drug (afamelanotide 16mg) to treat xeroderma pigmentosum (XP).

XP is a disease characterised by an inborn insufficiency to repair DNA damaged by sun exposure. Patients develop frequent skin cancers from an early age, with most experiencing their first malignancy before adolescence, and must avoid all forms of UV exposure.

The disease has a high mortality rate, with a median life expectancy of 30 years. At present, XP treatment is limited to management of symptoms, in particular regular surgery to remove cancerous lesions. An estimated 1 in 450,000 individuals in Europe suffer from XP.

CLINUVEL has high hopes for SCENESSE, noting that it belongs to a group of hormones which have been shown to reduce UV-induced damage to DNA and assist in DNA regeneration.

It took a step closer towards finding out whether SCENESSE is a viable treatment for XP this morning when it announced that the first patient diagnosed with XP has been administered the drug under a Special Access Program.

Initially, the patient’s safety will be evaluated over six weeks of treatment. Following confirmation of the safety of the drug product in this patient, CLINUVEL will conduct two further studies as part of the DNA Repair Program. Both studies will evaluate the impact of treatment with SCENESSE on DNA damage and restoration.

CLINUVEL’s Clinical Operations Manager, Dr Pilar Bilbao, commented: “We seek to provide meaningful benefit to XP patients, and these results will serve a wider population of fair-skinned individuals at risk of developing skin cancers. The next 12 months will be exciting for many patients, their families, the clinical experts and our own teams.”

More reading

• Here are the 10 most shorted ASX shares
• These were the best performing ASX 200 shares last week
• Up 9.2% in 1 day, is the Clinuvel Pharmaceuticals (ASX:CUV) share price a buy?
• ASX 200 rises 0.5%, gold miners glitter
• ASX 200 up 0.7%: Nearmap (ASX:NEA) launches capital raising, Afterpay (ASX:APT) rebounds

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the Clinuvel (ASX:CUV) share price is storming higher today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3mliWbL

The Catapult Group International Ltd (ASX: CAT) share price is pushing higher in morning trade on Tuesday.

At the time of writing the sports analytics and wearables company’s shares are up over 2% to $1.94.

Why is the Catapult share price charging higher?

Investors have been buying Catapult’s shares after it announced another potentially lucrative deal.

According to the release, the French Ligue Nationale de Rugby (LNR) has appointed Catapult as the preferred supplier of technology to all teams that compete in France’s Top 14 and Pro D2 professional rugby competitions for the next four years.

The company revealed that it was awarded the contract following an extensive due diligence and competitive tender process.

As part of the award, Catapult will support data exchange between any contracted club teams and the France national rugby union team in a seamless two-way data sharing process.

Management notes that Catapult’s proficiency in large-scale, high-security data aggregation and distribution stood out during the tender process. It was also supported by its experienced local support staff, rugby-specific performance metrics (scrum analytics, kick analysis, contact involvement, amongst others), and the company’s rich history with scientific validation.

The LNR commented: “The Ligue Nationale de Rugby and the Fédération Française de Rugby (FFR) are delighted with the choice of Catapult to optimise the monitoring of rugby players with a view to the 2023 World Cup. This choice follows a tender process that began in October 2019.”

Strong presence in rugby.

The company notes that this is the latest federation-wide rugby deal that Capapult has signed following similar deals in Australia, Scotland, and Wales.

Catapult’s Chief Commercial Officer, Matt Bairos, believes its technology and customer obsession are playing a key role in these awards.

He said: “After a lengthy tender process where our technology and people were reviewed comprehensively, it is motivating to know our level of customer obsession was a deciding factor in this award from such a world-class association. We look forward to delivering French rugby constant innovation and assisting them in their long-term strategy for player health and continued global success.”

The Catapult share price is now up 24% year to date.

More reading

• How the China rift could spur these ASX tech share prices to new records
• Why Splitit and these ASX shares just hit new highs
• Brokers name 3 ASX shares to buy right now
• Catapult share price in focus after strong FY 2020 growth
• Catapult share price surges on award of record contract

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Catapult Group International Ltd. The Motley Fool Australia has recommended Catapult Group International Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Catapult (ASX:CAT) share price charges higher on French Rugby deal appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/33qMNXT

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Less than a week after investors learned that AstraZeneca (NYSE: AZN) had paused the clinical trials testing its coronavirus vaccine, AZD1222, the UK’s Medicines Health Regulatory Authority (MHRA) determined it was safe for the company to restart the studies.

The pause was triggered by an adverse event – clinical-trial speak for a potential side effect – in one participant in the clinical trial. Pauses, which are fairly common in large clinical trials, give companies time to determine if the adverse event was caused by the vaccine. An independent committee for the UK studies reviewed the data and recommended to the MHRA that the clinical trials were safe to resume.

About 18,000 people have been vaccinated with AZD1222, which is also being tested in phase 3 clinical trials in Brazil, South Africa, and the US AstraZeneca didn’t say when the clinical trials outside of the UK would be restarted.

AstraZeneca also didn’t disclose publicly what the illness was, but multiple sources have reported that the company’s CEO Pascal Soriot said on a call organised by the investment bank J.P. Morgan that the patient experienced serious neurological symptoms that were consistent with transverse myelitis, a spinal inflammatory disorder.

Shares of AstraZeneca were up just 0.7% in late-afternoon trading on the news, but the drugmaker had already regained most of the decline its shares suffered after the clinical-trial pause was disclosed.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• Pfizer says it could know if its COVID-19 vaccine candidate works in October
• The surefire vaccine winner following AstraZeneca’s COVID-19 trial pause
• What if more than one company wins the coronavirus vaccine race?
• Coronavirus vaccine race: 7 key things you’ll want to know
• AstraZeneca coronavirus vaccine clinical trial paused

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post AstraZeneca resumes UK clinical trials of its coronavirus vaccine after a safety pause appeared first on Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from Motley Fool Australia https://ift.tt/33wrbZU

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Pfizer Inc (NYSE: PFE) is conducting one of the most advanced trials of a vaccine for COVID-19, and CEO Albert Bourla told an interviewer on Sunday that the drugmaker could know if its candidate is effective by the end of October.

The healthcare company is researching a slate of possible vaccines in partnership with BioNTech (NASDAQ: BNTX), and a phase 2/3 study evaluating its most advanced coronavirus vaccine candidate, BNT162b2, began in July. That trial is structured to include a total of 30,000 participants who will be given two doses of the vaccine, 21 days apart.

The assertion that the trial will have garnered enough data by the end of next month for the company to determine whether it’s ready to seek emergency use authorisation from the Food and Drug Administration comes as the healthcare companies have requested permission to increase enrollment in it to as many as 44,000 people. That would allow them to include volunteers as young as 16 years old, as well as people with pre-existing viral infections such as HIV and hepatitis B and C.

If BNT162b2 proves sufficiently effective to earn a thumb’s up from the FDA, Pfizer and BioNTech believe they’ll be able to provide up to 100 million doses of it by the end of 2020, and up to 1.3 billion doses by the end of 2021. Previously, the companies signed agreements to supply up to 600 million doses to the United States and up to 200 million doses to the European Union beginning later this year. Also, a deal with Japan would see up to 120 million doses sent to that country in the first half of 2021.

Although Bourla’s statement about the clinical trial timeline is encouraging, there are no guarantees that the timing won’t shift, or that the vaccine will prove effective enough. Last week, the phase 3 study of AstraZeneca‘s rival COVID-19 vaccine candidate was placed on a temporary hold so that researchers could evaluate an isolated safety signal –a good reminder of the uncertainty associated with all such human trials.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• The surefire vaccine winner following AstraZeneca’s COVID-19 trial pause
• What if more than one company wins the coronavirus vaccine race?
• Coronavirus vaccine race: 7 key things you’ll want to know
• AstraZeneca coronavirus vaccine clinical trial paused
• How to invest in coronavirus vaccine stocks

Todd Campbell owns shares of Pfizer. His clients may have positions in the companies mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Pfizer says it could know if its COVID-19 vaccine candidate works in October appeared first on Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from Motley Fool Australia https://ift.tt/32uRvV9

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Investing your money is a great way to grow wealth and set yourself up for a secure future. But if you’re going to invest, the last thing you’ll want to do is fall victim to these blunders that could leave you broke and miserable.

1. Panic selling

When the stock market crashes (which happens more often than we’d like), it’s easy to immediately panic and start selling off investments before their value tumbles even more. But if you go that route, you’re likely to lock in losses that could’ve otherwise been avoidable.

Remember, you only lose money in stocks when you sell investments when they’re down. But some market downturns are only temporary, and if you sit back and ride them out, your portfolio can recover. Just look at what happened earlier this year. In March, stocks plunged into bear market territory, and many investors were convinced we’d be in for a prolonged down market. Instead, those losses were erased by August.

2. Trying to time the market

Seasoned investors who have been following the stock market for years often struggle to time it, and the same thing is likely to happen to you. Predicting exactly when the broad market will rise or fall is extremely difficult, and it’s a strategy that could cause you to lose out on money for no good reason. Rather than attempt to time the market, pledge to invest consistently.

A strategy called dollar-cost averaging can help you in this regard. In short, dollar-cost averaging involves investing a certain amount of money at predetermined intervals. For example, you might decide to invest $100 a week in a specific stock or set of stocks, rather than attempt to buy $400 worth of stock at one low point during the month. This way, you’re more likely to end up with a lower average purchase price.

3. Holding losing stocks for too long

Not every stock you buy is guaranteed to be a winner, and frustrating as it may be to have an underperforming stock on your hands, you need to know when to cut your losses. If there’s a stock that’s been dropping in value since you bought it while the rest of your portfolio is thriving, you shouldn’t hesitate to cut the cord. Holding onto that stock for longer could mean watching its value sink even further.

For many people, investing is a work in progress. You might start out with a certain strategy only to have it evolve over time as your budget and appetite for risk change. But whether you’re first starting out as an investor or have been doing it for years, be sure to steer clear of the above mistakes. Doing so will help ensure that your portfolio serves you well, both in the near term as well as the long term.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• Pfizer says it could know if its COVID-19 vaccine candidate works in October
• 3 ASX shares with high-flying dividend yields
• Is the NEXTDC share price heading even higher from here?
• Will the Star Entertainment (ASX:SGR) share price boom in 2021?
• 3 ASX dividend shares to buy in a downturn

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post 3 major investing mistakes to avoid at all costs appeared first on Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from Motley Fool Australia https://ift.tt/33sJ4Jh

The NEXTDC Ltd (ASX: NXT) share price has been a very strong performer in 2020.

Since the start of the year the data centre operator’s shares have stormed 70% higher.

Is it too late to buy NEXTDC shares?

I don’t believe it is too late to buy NEXTDC’s shares. In fact, even after their strong gain this year, I feel they are good value for a long term investment.

This is due to the quality of its data centres and the increasing demand for its services thanks to the accelerating shift to the cloud.

One broker that agrees that NEXTDC is in the buy zone still is Goldman Sachs. This week the broker reaffirmed its buy rating and $13.20 price target on the company’s shares.

This price target implies potential upside of almost 19% for its shares over the next 12 months.

Why is Goldman positive on NEXTDC?

Goldman Sachs believes that there is still plenty of upside ahead for the NEXTDC share price despite its 70% gain in 2020.

It commented: “given the significant share price appreciation across 2020 YTD, many investors query the current trading multiples for NextDC (i.e., 22X FY21 EV/Sales vs. peer avg. of 12X) and question whether there is further upside from here.”

“We argue that given the significant contracted, but not yet billing MW [megawatts], along with material capacity options, a near term multiple based comparison is not necessarily reflective of the true value within this business, and note that should we incorporate the full revenue run-rate of its contracted, but not yet billing MW, along with its options, NextDC would be trading on an FY21 EV/Sales of 10X,” it explained.

Can the NEXTDC share price go even higher?

The broker has suggested that the NEXTDC share price could even go beyond its price target and all the way to $20.00.

Its analysts commented: “Our scenario analysis suggests that a value of $20 per share is possible for NextDC, based on assumptions that are high, but in our view not unrealistic considering the current acceleration in demand that is evident across the business.”

All in all, I think Goldman Sachs is spot on and NEXTDC would be a great addition to a balanced portfolio.

More reading

• Investing $1,000 into these ASX shares could be a very smart move
• How the China rift could spur these ASX tech share prices to new records
• 3 five-star ASX stocks to buy right now
• Brokers name 3 ASX shares to buy right now
• 3 quality ASX shares that could provide monster returns

Motley Fool contributor James Mickleboro owns shares of NEXTDC Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Is the NEXTDC share price heading even higher from here? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3kiWSgk

It’s been a struggle to find ASX shares that haven’t slashed their dividends due to difficult trading conditions. COVID-19 has certainly cast an unpredictable environment where once-considered ASX defensive shares have plummeted and retail shares soared.

While past performance is no guarantee for future results, I believe that any investor seeking high-flying dividend yields should look into these ASX shares. After all, it makes sense to get more bang for your buck.

Fortescue Metals Group Limited (ASX: FMG)

The Fortescue share price has stormed 60% higher since the new year. This has been underpinned by the company achieving record revenue in exports on the back of the rising spot price of iron ore.

I think that strong cash flows will continue for this mining outfit as it boasts the world’s lowest cost margins. Fortescue has heavily invested in its expansion and development plans.

The $1.7 billion Eliwana Mine and Rail project is expected to be completed by this December. It is estimated that the company will have a production run of 170 million tonnes per year for a 20-year life span. Fortescue shipped 178.2 million tonnes for the year ending 30 June 2020.

In addition, Fortescue declared a fully-franked dividend of $1.00 per share last month. Total dividends paid for the financial year stood at $1.76 representing a generous yield of 9.9%.

Harvey Norman Holdings Limited (ASX: HVN)

The multi-national retailer has had a bumper year thanks to the surge of a sales uptick during COVID-19. Despite temporary overseas store closures, Harvey Norman reported a record result for its full-year earnings in late August.

I believe the strong shift in consumer behaviour will have a continued impact going into 2021. Harvey Norman has already noted that sales in July and August have increased from the prior corresponding period. Furthermore, overseas sales have improved following the decision to loosen restrictions to the public.

Shareholders were rewarded with a fully franked dividend of 18 cents, a 50% increase on the 12 cents declared for 1H FY20 results. For the year based on the Harvey Norman share price, total dividend yield stands at 7%.

JB Hi-Fi Limited (ASX: JBH)

JB Hi-Fi has been another standout performer in 2020. The speciality discount retailer saw a 33.2% growth in profits which was underpinned by strong sales. Another contributor was the company’s low-cost operating model that was driven by productive floor space with high sales per square metre.

In JB Hi-Fi’s outlook, total sales in Australia had grown a massive 42.1% for the month of July and sales at the Good Guys were up 40.4%. While growth is anticipated to slow down due to the forced closure of its Melbourne stores, online sales growth has continued to accelerate.

The company flowed its profits through to a dividend pay-out of 90 cents. This was reflected a massive 76.5% increase on the prior year and brought the total dividends for the financial year to $1.89. A total dividend yield of 4.2% on top of the rising JB Hi-Fi share price.

Foolish takeaway

I think that all three of these ASX shares present a buying opportunity. Each of the companies have seen solid growth over the year and passed their profits onto shareholders. Should their fortunes continue, investors will be seeing new share price highs in the near future.

More reading

• Can the Harvey Norman (ASX:HVN) share price push higher in 2021?
• Top ASX dividend shares to buy in September 2020
• The latest ASX 200 stocks that top brokers just upgraded to “buy”
• Top brokers name 3 ASX shares to sell next week
• Are higher P/E ratios really here to stay?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post 3 ASX shares with high-flying dividend yields appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3iznKYT

2020 has been a tough year for the Star Entertainment Group Ltd (ASX: SGR) share price. Shares in the Aussie wagering group are down 32.4% as concerns over the coronavirus pandemic have spooked investors.

However, the Star Entertainment share price jumped 6.1% higher in yesterday’s trade to close at $3.15 per share. Here’s why this could be the start of a good run for the Aussie casino company.

Why the Star Entertainment share price can surge in 2021

Star owns and operates a number of casinos across Sydney, Brisbane and the Gold Coast. Earnings have slumped in 2020 as many of those venues have been forced to shut their doors.

On top of state-based restrictions, both domestic and international borders remain shut. That’s not good news for the casino industry which often relies on high-rolling international visitors to bring in the big bucks.

However, the Star Entertainment share price surged higher yesterday as some optimism returned to the market. On top of that, an article in the Australian Financial Review (AFR) noted Macquarie Group Ltd (ASX: MQG) has tipped Star as a potential outperformer in 2021.

Macquarie suggests that Star could benefit from the next phase of the pandemic recovery. Star is potentially a big winner from any successful vaccine in the form of higher foot traffic and earnings.

Importantly, Star now has exclusivity over the NSW poker machine market for casinos for the next 20 years following recent negotiations.

Fellow rivals like Crown Resorts Ltd (ASX: CWN) and SKYCITY Entertainment Group Limited (ASX: SKC) have also seen their values fall.

Is now the time to buy?

I think there’s little doubt that the Star Entertainment share price is a speculative buy right now.

Much of the next 12-18 months of share market performance relies on the vaccine success and economic recovery.

If we see a successful vaccine candidate in early 2021, I think Star Entertainment is one ASX share to put back in the buy zone.

More reading

• The best ASX stocks to buy for the COVID-19 recovery play
• The SkyCity (ASX:SKC) share price is up 20% in September. Here’s why…
• Top brokers name 3 ASX shares to sell today
• Top brokers name 3 ASX shares to buy today
• Half of ASX 200 stocks at risk as China-Australia relations hit new low

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Crown Resorts Limited and Sky City Entertainment Group Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Will the Star Entertainment (ASX:SGR) share price boom in 2021? appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2RteHwQ

The ASX dividend shares could be back in the buy zone. The August earnings season told me that many Aussie companies can still give investors a handy income stream.

It’s not as simple as just buying dividend shares, especially in the current market. I think it’s worth considering some companies with both upside potential and downside protection in 2020.

3 ASX dividend shares to buy in a downturn

I think Telstra Corporation Ltd (ASX: TLS) is worth a look. Telstra maintained its 16 cents per share dividend in its August full-year result.

That’s good news for shareholders and means management expects to maintain cash flow in the near-term. I think that 3.5% dividend yield gives Telstra shares some downside protection.

However, I also believe there is upside for Telstra. The company is shaping up as a leader in the 5G network space which could be good news for future earnings.

Telstra isn’t the only ASX dividend share that I like in 2021. The Super Retail Group Ltd (ASX: SUL) share price is up 2.6% for the year and could be climbing higher.

Super Retail has some strong brands like Supercheap Auto and Rebel Sport which I think could see further growth. The coronavirus pandemic has seen a spike in earnings but the medium-term is still looking good.

More time spent at home could be good news for home exercise sales while tighter economic conditions could see car repairs sales surge.

Super Retail shares are yielding 1.90% and the ASX dividend share could be a good buy for income and capital gains.

If Super Retail is a little too discretionary for your liking, I think Coles Group Ltd (ASX: COL) is worth a look.

The Coles share price is up 14.2% in 2020 with a 3.4% dividend yield. Coles’ supermarket earnings should be largely immune to an economic downturn.

That means the ASX dividend share could be a strong portfolio addition in the event of a downturn.

More reading

• Top ASX dividend shares to buy in September 2020
• How to position your ASX share portfolio for a downturn
• 3 simple ways to save more cash to buy ASX shares today!
• Is another stock market crash coming?
• Why I would buy Telstra (ASX:TLS) and this ASX dividend share

Motley Fool contributor Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Super Retail Group Limited and Telstra Limited. The Motley Fool Australia owns shares of COLESGROUP DEF SET. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post 3 ASX dividend shares to buy in a downturn appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3mg9Zkd